Allergy

After a developmental rollercoaster ride, the French firm is getting ready to refile Viaskin Peanut for 4-7 -year-olds in the first half of 2026.

A new report highlighting 62 key drug launches expected in 2026 includes five products that are predicted to hit a golden trifecta of being a first launch, having practice-changing potential and the promise of being a blockbuster.

Celltrion has won the race to launch the first biosimilar to Novartis/Roche’s blockbuster treatment for chronic spontaneous urticaria and severe persistent allergic asthma in Europe.

Novo Nordisk’s application seeking EU marketing approval to use its GLP-1 receptor agonist to treat cirrhotic metabolic dysfunction-associated steatohepatitis is one of 15 new drug filings the European Medicines Agency has started reviewing. Meanwhile, Arrowhead’s filing for its familial chylomicronemia syndrome, plozasiran, is being fast tracked.

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.